<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02353897</url>
  </required_header>
  <id_info>
    <org_study_id>Y-79-52120-201</org_study_id>
    <nct_id>NCT02353897</nct_id>
  </id_info>
  <brief_title>Patient and Physician's Satisfaction After a Long Term Treatment of Glabellar Lines With Dysport®</brief_title>
  <acronym>APPEAL</acronym>
  <official_title>An Assessment of Patient and Physician's Satisfaction After a Long Term Treatment of Glabellar Lines With Dysport®.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to look at patient and physician satisfaction of long term Glabellar lines
      (GL) treatment with Dysport in a real life setting. It will also allow better understanding
      of what patients expect from the treatment, and the injection practices used by doctors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To assess patient satisfaction regarding GL after three injection cycles of Dysport.</measure>
    <time_frame>Within 3 weeks ±7 days of visit 3</time_frame>
    <description>Assessed by patient auto questionnaire completion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To describe patient individual expectations.</measure>
    <time_frame>Within 3 weeks ±7 days of visit 1 and 2</time_frame>
    <description>Assessed by patient auto questionnaire completion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess patient satisfaction after one and two injection cycles of Dysport.</measure>
    <time_frame>Within 3 weeks ±7 days of visit 1 and 2</time_frame>
    <description>Assessed by patient auto questionnaire completion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe factors associated with patient satisfaction such as attractiveness, self-esteem, self-perceived age, desire to receive another injection.</measure>
    <time_frame>Within 3 weeks ±7 days of visit 1 and 2</time_frame>
    <description>Assessed by patient auto questionnaire completion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the GL severity (at rest and maximum frown) as per usual practice.</measure>
    <time_frame>Baseline (visit 1) and visit 3</time_frame>
    <description>Physician assessment using GL severity scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess physician satisfaction after one and three injection cycles of Dysport.</measure>
    <time_frame>Visit 1 follow up visit and visit 3 follow up visit (if performed)</time_frame>
    <description>5 point Likert scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe Dysport injection practices: muscles injected, total injected units, total volume injected, number of injection points and interval between injections.</measure>
    <time_frame>From visit 1 until the end of the study</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">150</enrollment>
  <condition>Glabellar Lines</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Private practices and clinics
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patient with moderate to severe GL naïve of any type of aesthetic
             treatment/procedure (invasive and non-invasive) for GL who provided written informed
             consent to take part.

          -  Patient who has prior to and independent of the study decided to undergo long term
             treatment of GL only (at least three cycles).

          -  Patient able to comply with the protocol (completion of web questionnaires).

          -  Patient whom physician intended to treat with Dysport independent of participation in
             the study.

        Exclusion Criteria:

          -  Patient already included in this study.

          -  Participation in an interventional trial within 30 days prior to study entry.

          -  Patient who is at risk in terms of precautions, warnings, and contraindication (follow
             local Summary of Product Characteristics (SmPC) of Dysport).

          -  Female patient who is pregnant, nursing or planning a pregnancy during the study.

          -  Hypersensitivity to Dysport® or to its excipients.

          -  Presence of infection at the proposed injection sites.

          -  Presence of myasthenia gravis, Eaton Lambert syndrome or amyotrophic lateral
             sclerosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ipsen Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SouthDerm</name>
      <address>
        <city>Sydney</city>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ERASE</name>
      <address>
        <city>Victoria</city>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Laura Bariquelo Buratini</name>
      <address>
        <city>Botucatu</city>
        <zip>18603-390</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Estetická Dermatologie</name>
      <address>
        <city>Brno</city>
        <zip>60200</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BcD Clinic s.r.o.</name>
      <address>
        <city>Praha</city>
        <zip>14000</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laser Center DARUS</name>
      <address>
        <city>Almaty</city>
        <zip>050022</zip>
        <country>Kazakhstan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Haddad Clinics</name>
      <address>
        <city>Beirut</city>
        <zip>70920</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre of Aesthetic Medicine &quot;Chistie prudi&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>105062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Preventive Medicine Clinic &quot;Vallex M&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>117630</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Plastic Surgery Institute</name>
      <address>
        <city>Moscow</city>
        <zip>119002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FI IF &amp; TC &amp; apos; Eye microsurgery &amp; apos</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630071</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Aesthetic Medicine</name>
      <address>
        <city>St Petersburg</city>
        <zip>197110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kocaeli University School of Medecine Umuttepe</name>
      <address>
        <city>Kocaeli</city>
        <zip>41380</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Aesthetic medicine &quot;Ankor&quot;</name>
      <address>
        <city>Kyiv</city>
        <zip>03087</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Czech Republic</country>
    <country>Kazakhstan</country>
    <country>Lebanon</country>
    <country>Russian Federation</country>
    <country>Turkey</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2015</study_first_submitted>
  <study_first_submitted_qc>January 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2015</study_first_posted>
  <last_update_submitted>October 24, 2016</last_update_submitted>
  <last_update_submitted_qc>October 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

